Cilo Cybin Holdings (CCC) Fair Value & Analysis
Healthcare · ZA · Market cap 288M ZAR
Fair value as of: Jun 26, 2026
From 1 valuation models · updated 3 days ago
Fair value updated Jun 26, 2026 — revised from 0.7500 ZAR to 0.2300 ZAR (−69.3%) since Jun 24, 2026. Share price +5.6% over the past month.
Price vs Fair Value (7 months)
7‑month range 0.7368 ZAR – 2.92 ZAR · fair‑value band 0.1500 ZAR – 0.2900 ZAR · the 1.00 ZAR price screens above the 0.2300 ZAR fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Cilo Cybin Holdings (CCC) currently trades at 1.00 ZAR, while our model-based Fair Value estimate is 0.2300 ZAR — implying the stock looks roughly 77.0% overvalued today. We read business quality at 87/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 7.1M ZAR. Revenue grew 14.2% year over year. Net debt stands at 3.9M ZAR. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Cilo Cybin Holdings Limited cultivates, manufactures, and sells medical cannabis products worldwide. The company offers CBD, THC, and THCV distillates; THC and CBD crude; CBD, CBG, and CBN isolates; CBD Nano Oil; oil in bottles, cannabis flower, and cannabis vapes; and topicals, capsules, and device products. It also provides flower sourcing, formulation, manufacturing, and primary and secondary packaging services. In addition, the company operates an online shop for its products under the Brand Shop name. Cilo Cybin Holdings Limited was founded in 2018 and is based in Centurion, South Africa.
Revenue & earnings trend
FY2023 – FY2025 · reported fiscal years
Cilo Cybin Holdings reported revenue of 0 ZAR in FY2025 versus 0 ZAR in FY2023. Reported net income was −586K ZAR in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥49.36 | ¥30.99 | -37% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.60 | HK$15.73 | -47% |
| Divi's Laboratories Limited DIVISLAB | ₹6,747 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Cilo Cybin Holdings (CCC) undervalued?
What is the fair value of CCC?
What is the quality score of CCC?
What is the revenue of Cilo Cybin Holdings (CCC)?
What is the net profit margin of CCC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.